PSYCH up2date, Table of Contents Psychiatrie und Psychotherapie up2date 2010; 4(05): 297-304DOI: 10.1055/s-0030-1248515 Schizophrenien und andere psychotische Störungen Neues zur Genetik der Schizophrenie Authors Rainald Mössner Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) Full Text References Literatur Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses.. Neurosci Biobehav Rev 2005; 29: 1021-1034 Barr RS, Culhane MA, Jubelt LE. et al. The effects of transdermal Nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.. Neuropsychopharmacology 2008; 33: 480-490 Zabala A, Eguiluz JI, Segarra R. et al. Cognitive performance and cigarette smoking in first-episode psychosis.. Eur Arch Psychiatry Clin Neurosci 2009; 259: 65-71 Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.. Biochem Pharmacol 2007; 74: 1182-1191 Graham FK. Presidential Address, 1974. The more or less startling effects of weak prestimulation.. Psychophysiology 1975; 12: 238-248 Cadenhead KS, Swerdlow NR, Shafer KM. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits.. Am J Psychiatry 2000; 157: 1660-1668 Quednow BB, Frommann I, Berning J. et al. Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.. Biol Psychiatr 2008; 64: 766-773 George TP, Termine A, Sacco KA. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of Nicotinic receptor mechanisms.. Schizophr Res 2006; 87: 307-315 Hong LE, Wonodi I, Lewis J. Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients.. Neuropsychopharmacology 2008; 33: 2167-2174 Bierut LJ, Stitzel JA, Wang JC. et al. Variants in Nicotinic receptors and risk for Nicotine dependence.. Am J Psychiatry 2008; 165: 1163-1171 Weiss RB, Baker TB, Cannon DS. et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent Nicotine addiction.. PLoS Genet 2008; 4: e1000125 Caporaso N, Gu F, Chatterjee N. et al. Genome-wide and candidate gene association study of cigarette smoking behaviors.. PLoS One 2009; 4: e4653 Petrovsky N. et al. Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.. Neuropsychopharmacology 2010; 35: 1429-1439 Quednow BB, Kuhn KU, Mössner R. et al. Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms.. Biol Psychiatry 2008; 64: 434-437 Quednow BB, Wagner M, Mössner R. et al. Sensorimotor Gating of Schizophrenia Patients Depends on Catechol O-Methyltransferase Val158Met Polymorphism.. Schizophr Bull 2010; 36: 341-346 Roussos P, Giakoumaki SG, Bitsios P. The dopamine D(3) receptor Ser9Gly polymorphism modulates prepulse inhibition of the acoustic startle reflex.. Biol Psychiatry 2008; 64: 235-240 O’Donovan MC, Craddock N, Norton N. et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up.. Nat Genet 2008; 40: 1053-1055 Ruano D, Aulchenko YS, Macedo A. et al. Association of the gene encoding neurogranin with schizophrenia in males.. J Psychiatr Res 2008; 42: 125-133 Stefansson H, Ophoff RA, Steinberg S. et al. Common variants conferring risk of schizophrenia.. Nature 2009; 460: 744-747 de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders.. Neuropsychopharmacology 2009; 34: 159-172 Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.. Mol Psychiatry 2007; 12: 707-747 Mössner R, Schuhmacher A, Kuhn K. et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.. Pharmacogenet Genomics 2009; 19: 91-94 Reynolds GP, Arranz B, Templeman LA. et al. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients.. Am J Psychiatry 2006; 163: 1826-1829 Wang L, Fang C, Zhang A. et al. The –1019 C / G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.. J Psychopharmacol 2008; 22: 904-909 Mössner R, Marshall CR, Sutcliffe JS. Contribution of SHANK3 mutations to autism spectrum disorder.. Am J Hum Genet 2007; 81: 1289-1297 Redon R, Ishikawa S, Fitch KR. et al. Global variation in copy number in the human genome.. Nature 2006; 444: 444-454 Marshall CR, Noor A, Vincent JB. et al. Structural variation of chromosomes in autism spectrum disorder.. Am J Hum Genet 2008; 82: 477-488 Stefansson H, Rujescu D, Cichon S. et al. Large recurrent microdeletions associated with schizophrenia.. Nature 2008; 455: 232-236
